Key Findings
The North American cancer biomarker market is all set to expand with a CAGR of 10.41% between the forecasted years of 2019-2027. The region holds the highest share in the global cancer biomarker market and also contribute the maximum revenue in the year 2018. The development in the precision and speed of diagnosis and rising production of highly specific drugs are majorly responsible for the surge in the North American cancer biomarker market.

Market Insights
The government institutions and private organizations have initiated to invest huge funds in enhancing research activities for cancer. This is one of the major factor augmenting the market growth in the region. Moreover, the developed economies like the United States and Canada are also majorly contributing to the market. However, rigorous regulatory agenda and a dearth of skilled workers are the growing concerns to the market.

Competitive Insights
Some of the leading companies in the market are Illumina, Inc., Diadexus Inc. (Acquired By Diazyme Laboratories), Abbott Laboratories, Agilent Technologies, Inc., Becton Dickinson and Company, Roche Diagnostics Ltd, Sanofi, Agendia N.V., Aureon Biosciences, Inc., Astellas Pharma Inc., Celgene Corporation, Clarient, Inc. (Acquired By Neogenomics Laboratories), Bristol-Myers Squibb, Beckman Coulter and Qiagen N.V.